A new Lyme disease vaccine made by Pfizer could lower infection rates.

A new Lyme disease vaccine made by Pfizer and Valneva could lower infection rates of the tick-borne illness, but federal ...

Enrolling Phase 2 DAYBreak CLL-201 bexobrutideg trial designed to support Accelerated Approval in relapsed/refractory chronic lymphocytic ...

Experienced R&D leader with a track record of advancing innovative therapies from early development to global approval — RESEARCH TRIANGLE ...

Gronvall reminded the audience there are currently two vaccines that do work to prevent cancer: the hepatitis B vaccine given ...

Vaccine maker's critics hope for new attorney general to reverse Pam Bondi's hostility to clinical trial whistleblower's ...

Vaccine makers Pfizer and BioNTech halted a large U.S. trial of their updated COVID-19 ​vaccine in healthy adults aged 50 to ...

COVID-19 partners Pfizer and BioNTech have been unable to recruit healthy adults aged 50 to 64 fast enough to deliver ...

Pfizer and Valneva are moving forward with regulatory approval for their experimental Lyme disease vaccine after it ...

In the world of clinical trials, missing the primary endpoint of a pivotal trial typically spells real trouble for a drug ...

A new vaccine to prevent Lyme disease in humans may soon be available. Pfizer said it's planning to seek regulatory approval.

When Lyme disease makes the news, it's typically not for positive reasons — but Pfizer is gearing up to seek regulatory ...